Ken Griffin Palisade Bio, Inc. Transaction History

Citadel Advisors LLC

  • $505 Billion
  • Q3 2024

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Nov 14, 2022
BUY
$0.11 - $83.85 $3,112 - $2.37 Million
28,299 New
28,299 $3,000

About PALISADE BIO, INC.

PALI Quotes by TradingView
  • Ticker PALI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 71,240,200
  • Market Cap $126M
  • Description
  • Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing oral therapies that target serious diseases associated with the breakdown of the mucosal barrier protecting the gastrointestinal tract. Its lead therapeutic candidate is LB1148, an oral liquid formulation of the digestive enzym...
More about PALI
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email